Abstract
Abstract: :
Purpose: To compare the IOP–lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in African Americans with glaucoma or ocular hypertension. Methods: Randomized, investigator–masked, multicenter, parallel–design clinical trial. After completing a washout of all ocular hypotensive agents, patients were randomized to bimatoprost QD (n=25) or travoprost QD (n=24) for 3 months. Study visits were at baseline and months 1, 2, and 3. The primary outcome measure was IOP. Results: There were no significant differences in baseline mean IOP (P=.146). Bimatoprost provided lower mean IOP than travoprost at the month 2 and 3 study visits. After 2 months of study medication, the mean IOP in the bimatoprost group was 17.7 mm Hg and 19.2 mm Hg in the travoprost group (P=.043). After 3 months, the mean IOP was 16.8 mm Hg in the bimatoprost group and 18.5 mm Hg in the travoprost group (P=.068). Mean IOP reductions ranged from 6.2 to 8.0 mm Hg (25.8% to 32.5%) with bimatoprost and from 5.9 to 6.9 mm Hg (23.2% to 27.6%) with travoprost. Conclusions: The findings of the present study suggest that bimatoprost is more effective than travoprost for IOP–lowering in African Americans with glaucoma or ocular hypertension.
Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials